Waystar Holding Corp. is a healthcare payments software company that provides cloud-based, AI-powered solutions to streamline revenue cycle management for healthcare providers. The company's platform automates payment-related workflows, including pre-encounter eligibility checks and prior authorizations, mid-encounter clinical documentation integrity and coding, and post-encounter claims submission, denial recovery, and patient financial care. Waystar serves a diverse client base of over 30,000 organizations, including physician practices, clinics, surgical centers, laboratories, and large hospital systems across the United States. Its proprietary AI engine, Waystar AltitudeAI, leverages machine learning and large language models to enhance claim accuracy and reduce administrative labor costs. The company was formed in 2017 through the merger of two established healthcare technology companies and has since expanded through strategic acquisitions, including Iodine Software. Waystar’s solutions are designed to improve reimbursement efficiency and provide a modern financial experience for patients while helping providers optimize their financial performance.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Software - Application Homepage waystar.com
Sector Technology IR page waystar.com
Tags
revenue cycle management, healthcare payments, claims processing, denial management, prior authorization, clinical documentation integrity, patient financial care, eligibility verification, ai-powered software, cloud-based platform, Waystar AltitudeAI, Iodine Software, Waystar True North, Advanced Propensity to Pay, Clinical Integrity + Revenue Capture, Claim + Payer Payment Management, Denial + Appeal Management, Financial Clearance, Analytics + Reporting
Press page waystar.com/news

Metrics

Valuation  
Market cap $ 5.527B
Market cap (USD) $ 5.527B
P/E 41.66
PEG —
P/BV 1.37
P/S 4.38
P/OCF 17.56
P/FCF 20.93
Dividend yield —
Turnover / mcap —
Returns  
ROE 3.2%
ROI 2.1%
ROIC 3.0%
Profit margin 10.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 36.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 43
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 1.099B 943.549M 791.01M 704.874M 578.565M
Net profit 112.089M -19.125M -51.334M -51.455M -47.116M
Free cash flow 283.192M 142.5M 29.943M 85.201M 91.865M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 32.75 36.7 — — —
Price performance 12m -0.11 — — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 126M 145M 177M
↳ YoY growth +15.2% +21.9%
Borrowings, current (USD) — — 18M 11.7M 14.2M
Borrowings, non-current (USD) — — 2.2B 1.22B 1.46B
Lease liabilities (USD) — — 31.7M 30.9M 18M
Cash and deposits (USD) 54.5M 72.6M 35.6M 182M 61.4M
Intangible assets (USD) — — 1.19B 1.04B 1.29B
Right-of-use assets (USD) — — 10.4M 10.8M 13M
Net debt (borrowings + leases - cash) (USD) — — 2.21B 1.08B 1.43B
Cash flow detail
Operating cash flow (USD) — 103M 51.5M 170M 310M
Purchases of property, plant and equipment (USD) — -17.4M -21.5M -27.3M -26.5M
Change in receivables (cash effect) (USD) — -17.4M -16.7M -21.8M -7.32M
Change in payables (cash effect) (USD) — -3.34M 11.9M 18.2M 8.93M
Share buybacks (cash effect) (USD) — -2.45M -688,000 -844,000 0.00
Interest paid (cash effect) (USD) — -144M -193M -123M -81.7M
Income taxes paid (cash effect) (USD) — -5.57M -51.4M -51.1M -31.7M
Share-based compensation (USD) — 8M 8.85M 54.4M 42.1M
Operating cash flow before change in receivables (USD) — 120M 68.2M 192M 317M
Free cash flow (OCF - PPE - intangibles) (USD) — 85.2M 29.9M 143M 283M
Income detail
Research and development expense (USD) — 32.8M 35.3M 48.8M 54.6M
Total comprehensive income (USD) — -21.1M -65.4M -34M 111M
Comprehensive income to owners (USD) — -21.1M -65.4M -34M 111M
Provision for credit losses (USD) — 2.52M 2.42M 2.67M 3.32M
Credit cost ratio (credit losses / average receivables) (%) — — — 2.0% 2.1%
Reported Feb 18, 2025 Feb 18, 2025 Feb 18, 2025 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Waystar Reports Third Quarter 2026 Results Bull 4 Bear 0 Results

Published on November 2, 2026

Q3 revenue of $325.6M, up 21% year over year

Q3 net income of $31.0M and non-GAAP net income of $87.1M

Q3 net income margin of 10%; adjusted EBITDA margin of 43%

LEHI, Utah and LOUISVILLE, Ky., November 2, 2026 — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the third quarter ended September 30, 2026.

“Waystar delivered another quarter of robust bookings and healthy demand across the business,” said Matt Hawkins, Chief Executive Officer of Waystar. “Providers are increasingly consolidating more of the revenue cycle onto Waystar’s connected platform, deepening relationships across both new and existing clients as they adopt more of our AI-powered capabilities. We are focused on executing against the opportunities in front of us and extending our market leadership as we leverage AI and agentic capabilities to reshape the revenue cycle.”

Third Quarter 2026 Financial Highlights

  • Revenue of $325.6 million, up 21% year-over-year
  • Net income of $31.0 million, GAAP net income per diluted share of $0.16, and net income margin of 10%
  • Non-GAAP net income of $87.1 million and non-GAAP net income per diluted share of $0.44
  • Adjusted EBITDA of $139.3 million and adjusted EBITDA margin of 43%
  • Cash flow from operations of $103.9 million and unlevered free cash flow of $114.8 million

Key Performance Metrics and Revenue Disaggregation

  • 1,488 clients contributed over $100,000 in LTM revenue, up 14% year-over-year
  • Net revenue retention rate (NRR) of 108%
  • Third quarter 2026 subscription revenue of $180.7 million, up 34% year-over-year
  • Third quarter 2026 volume-based revenue of $142.9 million, up 8% year-over-year
  • Third quarter 2026 provider revenue of $243.4 million, up 28% year-over-year
  • Third quarter 2026 patient revenue of $82.2 million, up 5% year-over-year

Financial Outlook

As of November 2, 2026, Waystar provides the following guidance for its full fiscal year 2026.[1]

  • Total revenue is expected to be between $1.277 billion and $1.287 billion
  • Adjusted EBITDA is expected to be between $543 million and $549 million
  • Non-GAAP net income is expected to be between $322 million and $337 million
  • Diluted non-GAAP net income per share is expected to be between $1.63 and $1.71

Webcast Information

Waystar will discuss its financial results on a conference call scheduled at 4:30 p.m. Eastern Time today, November 2, 2026. A live audio conference call will be available on Waystar’s website at https://investors.waystar.com/news-events/events . Waystar will archive the webcast on its site for those unable to listen in real time. This earnings release and the related Current Report on Form 8-K, furnished November 2, 2026, are available on the Investor Relations page of Waystar’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts.

Non-GAAP Financial Measures

To supplement the consolidated financial statements prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release contains certain non-GAAP financial measures as defined below. We present non-GAAP financial measures as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses adjusted EBITDA and adjusted EBITDA margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management uses non-GAAP net income and non-GAAP net income per share to evaluate our core operating profitability on an after-tax basis exclusive of certain non-cash and non-recurring items that Management does not believe are indicative of our core operating performance, and to facilitate comparison with peer companies that may have different capital structures, acquisition histories, or tax profiles. Management uses non-GAAP operating expenses to evaluate trends in our cost structure excluding the items above. Management uses unlevered free cash flow to evaluate cash generation from our core business operations independent of our capital structure. Management uses net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio to evaluate our capital structure and leverage. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.

Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income, non-GAAP net income per share, non-GAAP operating expenses, unlevered free cash flow, net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio are not recognized terms under GAAP and should not be considered as an alternative to net income (loss), net income (loss) margin or the related GAAP expense line items as measures of financial performance, cash provided by operating activities as a measure of liquidity, total debt as a measure of indebtedness, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. A quantitative reconciliation of the forward-looking non-GAAP financial measures included in our financial outlook is not provided for the reasons described under “Financial Outlook.” Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

The following non-GAAP financial measures and key performance metrics are defined below:

Adjusted EBITDA and adjusted EBITDA Margin

We define adjusted EBITDA as net income / (loss) before interest expense, net, income tax expense / (benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition, integration and transaction costs, asset and lease impairments, costs related to amended debt agreements, IPO and secondary offering costs and costs related to other unusual, non-recurring or otherwise notable items. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Non-GAAP Net Income and Non-GAAP Net Income Per Share

We define non-GAAP net income as GAAP net income excluding the impact of stock-based compensation, acquisition, integration and transaction costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, costs related to amended debt agreements and amortization of intangibles, and costs related to other unusual, non-recurring or otherwise notable items. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period-specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate. Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.

Unlevered Free Cash Flow

We define unlevered free cash flow as cash from operations plus cash interest paid less capital expenses.

Net Debt

We define net debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization less cash and equivalents and investment securities.

Adjusted Net Leverage Ratio

We define adjusted net leverage ratio as net debt divided by adjusted EBITDA over the preceding twelve months.

Gross Debt

We define gross debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization.

Adjusted Gross Leverage Ratio

We define adjusted gross leverage ratio as gross debt divided by adjusted EBITDA over the preceding twelve months.

Key Performance Metrics

Net Revenue Retention Rate

Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve-month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.

Customer Count with >$100,000 of Revenue

We regularly monitor and review our count of clients who generate more than $100,000 of revenue.

Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, statements regarding Waystar’s expectations relating to future operating results and financial position, including full year 2026, and future periods; the performance of our new product offerings; our industry and market opportunities, business strategy, goals, and expectations concerning our market position, future operations, margins and profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. Forward-looking statements include all statements that are not historical facts. These statements may include words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “outlook,” the negative version of these words or similar terms and phrases to identify forward-looking statements in this press release, including the discussion of outlook for full fiscal year 2026.

The forward-looking statements contained in this press release are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. The following factors are among those that may cause actual results to differ materially from the forward-looking statements: our operation in a highly competitive industry; our ability to retain our existing clients and attract new clients; our ability to successfully execute on our business strategies in order to grow; our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the acquisition of Iodine; our ability to establish and maintain strategic relationships; the growth and success of our clients and overall healthcare transaction volumes; consolidation in the healthcare industry; our selling cycle of variable length to secure new client agreements; our implementation cycle that is dependent on our clients’ timing and resources; our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees; the accuracy of the estimates and assumptions we use to determine the size of our total addressable market; our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards; the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures; the performance and reliability of internet, mobile, and other infrastructure; the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions; our reliance on certain third-party vendors and providers; any errors or malfunctions in our products and solutions; failure by our clients to obtain proper permissions or provide us with accurate and appropriate information; the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards; our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks; increases in card network fees and other changes to fee arrangements; the effect of payer and provider conduct which we cannot control; privacy concerns and security breaches or incidents relating to our platform or data (including personal information and other regulated data); the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity; our ability to adequately protect and enforce our intellectual property rights; our ability to use or license data and integrate third-party technologies; the development, deployment, and use of AI; our use of “open source” software; legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights; claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties; the heavily regulated industry in which we conduct business; the uncertain and evolving healthcare regulatory and political framework; healthcare laws and data privacy and security laws and regulations governing our Processing of personal information (which may also be referred to as “personal data” or “personally identifiable information”); reduced revenues in response to changes to the healthcare regulatory landscape; legal, regulatory, and other proceedings that could result in adverse outcomes; contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act/anti-money laundering laws and regulations; existing laws that regulate our ability to engage in certain marketing activities; our full compliance with website accessibility standards; any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities; limitations on our ability to use our net operating losses to offset future taxable income; losses due to asset impairment charges; our substantial debt and restrictive covenants in the agreements governing our Credit Facilities; interest rate fluctuations; unavailability of additional capital on acceptable terms or at all; the impact of general macroeconomic conditions; our history of net losses and our ability to achieve or maintain profitability; the interests of certain investors may be different than the interests of other holders of our securities; and each of the other factors discussed under the heading of “Risk Factors” in the Company’s 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2026, and in other reports filed with the SEC, all of which are available on the Investor Relations page of our website at investors.waystar.com.

Any forward-looking statements made by us in this press release speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.

About Waystar

Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing approximately 1.5 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar’s enterprise-grade platform annually processes over 8.5 billion healthcare payment transactions, including over $3.0 trillion in annual gross claims and spanning approximately 60% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com .

[1] We have not reconciled the forward-looking adjusted EBITDA, non-GAAP net income, and non-GAAP net income per share guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

.

**Media Contact
**Kristin Lee
[email protected]

**Investor Contact
**Edward Parker
[email protected]

Waystar adds former JPMorgan president to its board

Longtime financial services leader Heidi Miller becomes Waystar’s newest board member.

Read more

Home / Newsroom / Waystar Reports Third Quarter 2026 Results

Sales

Contact support

Waystar footer logo

© 2026 Waystar. All rights reserved.

Search waystar

Search term

Search

Published on October 22, 2026

Study finds 42% of hospitals and health systems face at least $1 million in annual recoupment requests, as new research highlights growing demand for AI-powered automation

LEHI, Utah and LOUISVILLE, Ky., October 22, 2026 — Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, and Modern Healthcare today announced new research showing that payer recoupments create significant financial exposure, drain staff capacity, and make it harder for healthcare organizations to protect revenue after payment.  

The findings underscore a critical challenge for healthcare providers: financial risk does not end when a claim is paid. With payer recoupments growing twice as fast as overall claim volume¹, healthcare organizations face increasing pressure to protect reimbursement, improve financial predictability, and reduce administrative burden. 

The study, Recoupments: Gaining Visibility into Post-Payment Risk and Recovery, surveyed healthcare executives across hospitals, health systems, physician groups, ambulatory organizations, and post-acute providers.  

Key findings include: 

  • 42% of hospitals and health systems report at least $1 million in annual recoupment requests, including 10% reporting $25 million or more. 

  • 83% of healthcare organizations lack full visibility into the root causes of individual recoupments, while 90% lack full visibility into whether they could have been prevented. 

  • 74% report that post-payment adjustments affect cash flow forecasting, underscoring the challenge of maintaining financial predictability. 

  • 64% identify eligibility and coordination-of-benefits issues as leading recoupment drivers, while 57% cite coding and billing errors, highlighting opportunities to address risk earlier in the revenue cycle. 

“Healthcare providers have made progress in automating how they get paid, but protecting that revenue after payment remains a critical challenge,” said Matt Hawkins, Chief Executive Officer of Waystar. “These findings highlight why the next evolution of revenue cycle management must connect intelligence across the entire payment lifecycle. With AI-powered automation, providers can stop reacting to recoupments and start identifying risk earlier, reducing manual work and preventing avoidable financial losses.” 

Growing interest in AI and automation signals opportunity for broader adoption 

While one-third (33%) of respondents currently use AI or automation in some capacity, another 43% are actively evaluating solutions. Healthcare leaders reported better visibility into payer rules (46%), automated end-to-end recoupment tracking (44%), and predictive AI to identify recoupments before they occur (36%) among the capabilities that would most improve recoupment management. 

Waystar is advancing this shift through its AI-powered platform, which connects payment data, payer intelligence, and automated workflows across the revenue cycle. Waystar Recoupment Manager helps providers automate matching and reconciliation, gain greater visibility into post-payment activity, and identify recurring issues that can inform upstream prevention. 

For example, using Waystar Recoupment Manager, Respiratory Technologies, a Waystar client, achieved an 86.5% recoupment match rate, reduced time spent per provider-level balance adjustment by 80%, and decreased complex adjustments by 10%. 

Download the full report, Recoupments: Gaining Visibility into Post-Payment Risk and Recovery,

to explore the findings and strategies for improving post-payment visibility, recovery, and prevention.  

Published on October 14, 2026

LEHI, Utah, and LOUISVILLE, Ky., October 14, 2026 — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced it will report financial results for the third quarter ended September 30, 2026, after market close on Monday, November 2, 2026. The company will discuss its financial results on a conference call at 4:30 p.m. Eastern Time that same day. 

A live audio webcast of the conference call will be available on Waystar’s investor relations website at https://investors.waystar.com/news-events/events

. The webcast will be archived on the site for those unable to listen in real time.  

Prompts

Waystar Holding Corp. (ticker WAY), listed in United States.

ETFs Holding Waystar Holding Corp.

ETF Weight in ETF Shares Market value As of
BCSM 1.40% 22,619 $ 464.368K Jun 30, 2026
LFSC 1.18% 57,012 $ 1.493M Aug 31, 2026
FMED 0.91% 18,000 $ 471.24K Aug 31, 2026
FFSM 0.35% 247,392 $ 5.222M Jul 31, 2026
TMAT 0.34% 38,385 $ 810.307K Jul 31, 2026
NBGX 0.33% 1,846 $ 48.328K Aug 31, 2026
PSC 0.25% 285,682 $ 5.865M Jun 30, 2026
DFSV 0.17% 1,657,896 $ 46.653M Nov 12, 2026
SYZ 0.15% 4,908 $ 100.761K Jun 30, 2026
GVLU 0.11% 9,776 $ 274.803K Nov 17, 2026
DFAS 0.08% 981,498 $ 27.619M Nov 12, 2026
DFAT 0.04% 490,226 $ 13.795M Nov 12, 2026
MKTN 0.04% 2,084 $ 42.785K Jun 30, 2026
SMDX 0.02% 907 $ 25.496K Nov 17, 2026
NBCR 0.02% 5,329 $ 139.513K Aug 31, 2026
DXUV 0.01% 13,819 $ 388.867K Nov 12, 2026
EBI 0.00% 26 $ 680.68 Aug 31, 2026